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Welcome Editorial to Trials in VaccinologyAs the cost of providing healthcare to American citizens threat-
ens to bankrupt the US economy, greater attention will be given to
methods of disease prevention: vaccines and lifestyle choices will
be in the van of extended efforts to deliver healthcare at an afford-
able cost. This situation is repeated in many developed and some
less developed countries. To meet this need for a greater emphasis
on disease prevention by vaccination, Elsevier launched the journal
‘‘Vaccine’’ some 30 years ago and is now ready to extend this initia-
tive by establishing ‘‘Trials in Vaccinology’’. This new Web-based,
peer reviewed, on-line journal will publish papers that can be
searched and cited. It will have additional features in that it will
be possible to link the location of the vaccine trials to embedded
Google Maps so as to get a more informed view of the nature
and value of that trial. This new journal will also provide a trans-
parent and comprehensive medium for bringing to general atten-
tion the myriad of trials of vaccines that presently are not
acceptable for publication in regular journals as they may lack sci-
entiﬁc novelty, do not deliver new insights or are designated as
lacking a cutting edge. But for those in the ﬁeld, the publication
of these trials is of vital signiﬁcance as they seek to extend and ex-
pand the application of vaccines of established efﬁcacy and safety
to new countries and populations. Trials in both the human and
veterinary areas will be considered for publication in this journal.
The testing of a vaccine in the ﬁeld does not end with the issu-
ance of a licence to manufacture. Each country or granting agency
needs to know if, in a particular population, vaccination with a new
vaccine is cost-effective. This may depend on the previous expo-
sure to disease or the prevalence of compromised immune sys-
tems. The sex, age, prosperity, state of stress, ethnicity and
environmental conditions that the test populations experience
may each affect the outcome of a vaccine trial. Such trials do not
have innovative science as a feature that enables them to satisfy
reviewers and editors of regular journals of science, rather they
portray the incremental improvements and adaptations to circum-
stances without which successful vaccination programs cannot be
achieved. This is vital information to those engaged in the ﬁeld
with vaccines and vaccination campaigns. So, the publication for
a wide readership of the methods of formulation and preparation,
details of storage conditions, transportation methods, ways in
which vaccines may be presented and delivered to a wary popula-
tion by fully qualiﬁed professionals and specially trained vaccina-
tion paramedics is of great value.
A necessary product of all these additional tests and trials will be
an enhanced appreciation of the side effects of the vaccine. As the
trials will be highly deﬁned there will be an opportunity to observe
and report any adverse effects of the vaccination. The corollary to1879-4378  2011 Published by Elsevier Ltd.
doi:10.1016/j.trivac.2011.12.001
Open access under CC BY-NC-ND license.this is that in the absence or paucity of such reports, the case which
asserts the safety of a vaccine is strengthened. This means that
accusations of vaccine caused damage in other parts of the world
will be that much harder to substantiate. The transparent and open
publication of such trials on the Web in a way that is available,
without payment, to the general public may go some way to allay-
ing the fears and suspicions of the vaccine rejectionists in the Anti-
vaccine Movements.
The publication of these trials also provides opportunities to ad-
vance the science of vaccinology. Gathering sera from a wide range
of immunised people and animals vaccinatedunder a variety of con-
ditions results in the collection ofmaterials fromwhich correlates of
protection may be gleaned. They will also yield vital data that en-
able the differentiation of people who have been vaccinated and
those who have been infected naturally. Additionally, it will be pos-
sible to observe and explore the way the vaccine affects the strains
of pathogen that prevail once widespread vaccination programmes
are in place. Tailoring the make up of the vaccine to the local condi-
tions will occasion more trials whose published results will inform
those who design campaigns for disease control and elimination.
It maybe that manufacturers set up production facilities in
developing countries which requires the testing of the resulting
vaccines in comparison with the licensed version that has already
achieved regulatory agency approval. Such tests will be adduced to
provide substantiation of the equivalence of the local vaccine to
the satisfaction of the local regulatory system. Reports of these tri-
als will constitute a body of knowledge that will inform those who
seek to control disease in the developing world of the details of the
methods and procedures that have to be followed so that vaccines
that are safe and efﬁcacious may be produced with regularity and
reliability.
One of the difﬁculties faced by thoseworking in the development
and production of vaccines is that the work they do in optimising
vaccine production processes by incremental improvements to the
yield, quality and economics of the process are not recognised and
rewarded by those who evaluate the contributions of workers in
the ﬁeld. Yet, without such efforts to optimise processes, it would
be difﬁcult for manufacturers to justify the expenditures and risks
ofmajor trial programs if theywere doubtful as to the eventual ben-
eﬁts to the company or organisation of proceeding with such
vaccines. ‘‘Trials in Vaccinology’’ provides an opportunity for scien-
tists, engineers, technologists, information and communication spe-
cialists, statisticians, economists and socio-political workers to
publish their contributions to progress in the improvements of pub-
lic health through making manifest both vaccines and vaccination
programmes.
Editorial / Trials in Vaccinology 1 (2012) 2–3 3While it is generally accepted that vaccines constitute one of
the most cost-effective ways of improving the health of people,
we still have much to do to achieve the level of social and ﬁnancial
commitment that this method of health promotion warrants. Min-
istries of Health, Granting Agencies, Regulatory Agencies, Social
Welfare Organisations and the established structures that govern
the Medical Profession are not yet fully appreciative of the value
of investments and efforts in vaccine based prophylaxis. The pub-
lication of this ‘‘Trials in Vaccinology’’ journal may provide the evi-
dence that adds weight to the contention that research and
development in the area that leads to effective and safe vaccines
should be on at least an equal status and level of support as work
in the area of therapeutics.
To the readers and authors who use this new journal I trust that
youwill ﬁnd it a valued addition to your armamentariumof facilitiesthat will both carry you forward in your careers and advance the
health andwell being of the animals andhumans of ourmultifarious
and wonderful societies.
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